2026 Dyslipidemia Guideline: Target-Driven Therapy and the End of the Nonstatin Stepladder

How the 2026 ACC/AHA guideline changes lipid clinic workflows with absolute LDL-C targets, non-sequential nonstatin selection, and universal Lp(a) testing.

dyslipidemiaACC/AHA guideline 2026LDL-C targetsbempedoic acidPCSK9 inhibitorsinclisiranLp(a)PREVENT calculatorezetimibestatin intoleranceCLEAR Outcomeslipid management Cardiology / Anticoagulation

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

📋 Reference Card

⚡ Bottom Line

The 2026 ACC/AHA dyslipidemia guideline restores absolute LDL-C targets (<55 mg/dL for very high-risk, <70 mg/dL for non-very high-risk ASCVD), eliminates the mandatory ezetimibe-first stepladder for nonstatin therapy, introduces the PREVENT risk calculator, and recommends universal Lp(a) testing at least once in adulthood.

Key Results

CLEAR Outcomes (bempedoic acid, PMID 37018772): 13% MACE reduction (HR 0.87, 95% CI 0.79-0.96) in statin-intolerant patients, making it the first oral nonstatin with CV outcomes benefit. 2026 guideline (PMID 41824590): absolute LDL-C targets replace percentage-reduction-only approach. Non-sequential nonstatin selection allows jumping directly to PCSK9i when LDL-C gap is large.

Clinical Interpretation

This guideline represents three genuine paradigm shifts: (1) the return to absolute LDL-C targets creates measurable, specific goals that justify combination therapy from the outset; (2) elimination of the nonstatin stepladder allows pharmacists to recommend the agent most likely to reach target based on the LDL-C gap; (3) universal Lp(a) testing identifies ~20% of the population with an independent, genetically determined risk factor that cannot be modified by lifestyle or statins.

Pharmacist Action Items

Update lipid clinic protocols to use absolute LDL-C targets: <55 mg/dL for very high-risk ASCVD, <70 mg/dL for non-very high-risk ASCVD.
Remove sequential nonstatin mandates: select ezetimibe, PCSK9i, bempedoic acid, or inclisiran based on the LDL-C gap to target, not a mandatory stepladder.
Champion bempedoic acid for statin-intolerant patients: oral, once-daily, with MACE reduction data (CLEAR Outcomes HR 0.87). No injection, less PA burden than PCSK9i.
Advocate for universal Lp(a) testing at least once in adulthood. Elevated Lp(a) (>=125 nmol/L) justifies more aggressive LDL-C lowering and identifies patients for future targeted therapies (pelacarsen, olpasiran in phase 3).
Learn the PREVENT risk calculator: it replaces the Pooled Cohort Equations with better calibration across race/ethnicity and incorporates social determinants of health.
Track percentage of patients at LDL-C goal as a measurable quality metric. Navigate PCSK9i and inclisiran prior authorizations efficiently; this remains a core pharmacist value-add.

2018 vs. 2026 Guideline Changes

Feature	Old	New
LDL-C targets	Percentage reduction (>=50%)	Absolute: <55 mg/dL (very high-risk), <70 mg/dL (non-very high-risk ASCVD)
Nonstatin sequencing	Stepwise: ezetimibe then PCSK9i	Non-sequential: select based on LDL-C gap to target
Risk calculator	Pooled Cohort Equations	PREVENT equations
Lp(a)	Mentioned as risk enhancer	Universal testing recommended once in adulthood
Bempedoic acid	Not available	First-line nonstatin option (CLEAR Outcomes)
Inclisiran	Not available	Option for durable LDL-C lowering (q6 month dosing)

Pivotal Trial

Name CLEAR Outcomes

Pmid 37018772

Finding Bempedoic acid reduced MACE 13% (HR 0.87, 95% CI 0.79-0.96) in statin-intolerant patients

Expected LDL-C Reductions by Agent

Ezetimibe 15-20%

PCSK9i 50-60%

Bempedoic Acid 15-25%

Guideline Context

2026 ACC/AHA Dyslipidemia Guideline (PMID 41824590, Circulation 2026) replaces the 2018 guideline. Key changes from 2018: absolute LDL-C targets (vs percentage reduction), non-sequential nonstatin selection (vs ezetimibe-first mandate), PREVENT calculator (vs Pooled Cohort Equations), Lp(a) testing recommendation, and elevated role for bempedoic acid based on CLEAR Outcomes.

Editor's Note

2026 ACC/AHA guideline PMID: 41824590. CLEAR Outcomes PMID: 37018772. Lp(a)-targeted therapies (pelacarsen, olpasiran) are in phase 3 trials as of 2026. PREVENT calculator replaces PCE but implementation timeline varies by EHR system.